Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tum...
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background:
Hyaluronan accumulation in tumour stroma is associated with reduced survival in preclinical cancer models. PEGPH20 degrades hyaluronan to facilitate tumour access for cancer therapies. Our objective was to assess safety and antitumour activity of PEGPH20 in patients with advanced solid tumours.
Methods:
In HALO-109-101 (
N
Alternative Titles
Full title
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5785735
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5785735
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/bjc.2017.327
